Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Q BioMed's pipeline boosted as tech partner gets funding for glaucoma therapeutic research

Partner Mannin Research Inc has received funding to carry out a proof of concept study for the treatment
Q BioMed's pipeline boosted as tech partner gets funding for glaucoma therapeutic research
The eyes have it...Mannin is researching a new therapeutic for glaucoma

Biotech accelerator firm Q BioMed Inc (OTCMKTS:QBIO) announced further progress in its bid to expand its pipeline.

Partner Mannin Research Inc has received funding to carry out a proof of concept study for a new therapeutic for eye condition  glaucoma, in which the optic nerve is damaged.

The R&D funding comes from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) and the number of potential patients demanding better treatments make this a multi-billion-dollar opportunity, says QBiomed.

The company has licensed the Mannin Tie2 technology, and is collaboratively developing the Tie2 platform for glaucoma, and other indications.

It has the potential to treat several additional, vascular related diseases, such as acute kidney injury, and cardiorenal syndrome.

"As our understanding about the Angiopoietin-Tie2 system grows, I am very excited about the clinical therapeutic possibilities," said Dr. Sarah Quaggin from Mannin.

The new biologic would be an additional product to the Mannin Tie2 pipeline.

Meanwhile,  Q BioMed said development of the MAN-01 small molecule for the treatment of primary open-angle glaucoma continues on-pace and is now at a point where the most active candidates will be selected for final testing and optimization as a soluble, topical eye drop that permeates well into the eye.

It is anticipated that pre-clinical IND enabling studies will begin in the second quarter of 2018.

Shares in New York eased 0.27% to US$3.69.

View full QBIO profile View Profile

Q BioMed Inc Timeline

Related Articles

the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
1511808112_surgeon.jpg
November 27 2017
In a letter to stakeholders, George Adams, the president and chief executive, highlighted that the device would "reduce the cost of its equipment significantly"

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use